TrialLancet (London, England)2019

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.

Richard Pratley et al.PubMed ↗Publisher ↗

No numbers read from the abstract.